Arcellx (ACLX)
(Delayed Data from NSDQ)
$58.94 USD
-0.11 (-0.19%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $58.95 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACLX 58.94 -0.11(-0.19%)
Will ACLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACLX
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
ACLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes (ALKS) Lags Q2 Earnings Estimates
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
Other News for ACLX
Arcellx Inc (ACLX) Q2 2024 Earnings: Revenue Surpasses Estimates at $27.4M, GAAP EPS Beats at -$0.51
Assessing Arcellx: Insights From 7 Financial Analysts
Analysts Are Bullish on These Healthcare Stocks: Royalty Pharma (RPRX), Arcellx Inc (ACLX)
Morgan Stanley Keeps Their Buy Rating on Arcellx Inc (ACLX)
Optimistic Buy Rating for Arcellx Inc: Promising Trial Developments and Strategic Partnerships Signal Strong Potential